How to Order Cyanokit
For related questions regarding Cyanokit®, please contact the BTG Specialty Solutions Center™ at 1-844-293-0007, or email Cyanokit@btgsp.com.
The following suppliers can fulfill orders for Cyanokit®:
Phone: (844) 222-2273
Phone: (800) 533-0523
Phone: (800) 569-0570
Phone: (877) 788-1100
Phone: (800) 843-7477
Phone: (631) 924-8223
Phone: (800) 472-4346
Phone: (800) 824-6016
Phone: (415) 983-8300
Phone: (800) 388-3833
Phone: (636) 240-1515
*Authorized Distributor of BTG
How Cyanokit® is supplied:
|NDC||Carton Dimensions |
| NDC 50633-310-11 ||W: 194 mm x L: 100 mm x H: 97 mm|
CYANOKIT is indicated for the treatment of known or suspected cyanide poisoning.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Emergency Patient Management
• In conjunction with CYANOKIT, treatment of cyanide poisoning must include immediate attention to airway patency, adequacy of oxygenation and hydration, cardiovascular support, and management of seizures. Consideration should be given to decontamination measures based on the route of exposure.
Risk of Anaphylaxis and Other Hypersensitivity Reactions
• Consider alternative therapies, if available, in patients with known anaphylactic reactions to hydroxocobalamin or cyanocobalamin.
• Allergic reactions may include: anaphylaxis, chest tightness, edema, urticaria, pruritus, dyspnea, and rash. Allergic reactions including angioneurotic edema have also been reported in postmarketing experience.
Risk of Renal Injury
• Acute renal failure with acute tubular necrosis, renal impairment and urine calcium oxalate crystals have been reported following CYANOKIT therapy. Monitor renal function for 7 days following CYANOKIT therapy.
Risk of Increased Blood Pressure
• Substantial increases in blood pressure may occur following CYANOKIT therapy. Monitor blood pressure during therapy.
• Because of its deep red color, hydroxocobalamin has been found to interfere with colorimetric determination of certain laboratory parameters (e.g., clinical chemistry, hematology, coagulation, and urine parameters). Be aware of this when reporting and interpreting laboratory results.
• While determination of blood cyanide concentration is not required for management of cyanide poisoning and should not delay treatment with CYANOKIT, collecting a pretreatment blood sample may be useful for documenting cyanide poisoning as sampling post-CYANOKIT use may be inaccurate.
• Because of its deep red color, hydroxocobalamin may cause hemodialysis machines to shut down due to an erroneous detection of a “blood leak”. This should be considered before hemodialysis is initiated in patients treated with hydroxocobalamin.
• Hydroxocobalamin absorbs visible light in the UV spectrum. It therefore has potential to cause photosensitivity. While it is not known if the skin redness predisposes to photosensitivity, patients should be advised to avoid direct sun while their skin remains discolored.
Pregnancy and Lactation
• Available data from cases reported in the published literature and postmarketing surveillance with CYANOKIT use in pregnant women are insufficient to identify a drug-associated risk for major birth defects, miscarriage, or adverse maternal and fetal outcomes. There are risks to the pregnant woman and fetus associated with untreated cyanide poisoning. In animal studies, hydroxocobalamin administered to pregnant rats and rabbits during the period of organogenesis caused skeletal and soft tissue abnormalities, including alterations in the central nervous system, at exposures similar to human exposures at the therapeutic dose.
• Breastfeeding is not recommended during treatment with CYANOKIT.
• The most common adverse reactions (>5%) include transient chromaturia, erythema, oxalate crystals in urine, rash, increased blood pressure, nausea, headache and infusion site reactions.